The PARADIGM International Liaison Group (PILG) is a co-creation hub acting as an operational platform to connect PARADIGM with like-minded initiatives.
These include key Innovative Medicine Initiatives and other international efforts focused on the co-development and implementation of patient engagement practices in medicines development.
![](https://imi-paradigm.eu/wp-content/uploads/2019/01/Paradigm_img-e1548691699138.jpg)
The PILG supports the members of the PARADIGM consortium to create a well-defined roadmap addressing the strategic and operational needs and resources for patient engagement, focusing on the three phases targeted by PARADIGM:
![](https://imi-paradigm.eu/wp-content/uploads/2019/01/science.png)
Research and
priority setting
![](https://imi-paradigm.eu/wp-content/uploads/2019/01/molecular.png)
Design of
clinical trials
![](https://imi-paradigm.eu/wp-content/uploads/2019/01/Shape.png)
Early dialogues with
regulators and HTA bodies
The PILG is instrumental, agile and aligned with PARADIGM’s scope in the following ways:
![](https://imi-paradigm.eu/wp-content/uploads/2019/01/chat-2.png)
provides advice to PARADIGM in developing relationships
![](https://imi-paradigm.eu/wp-content/uploads/2019/01/Group.png)
establishes an international vision of patient engagement
![](https://imi-paradigm.eu/wp-content/uploads/2019/01/icon.png)
reduces fragmentation and duplication
![](https://imi-paradigm.eu/wp-content/uploads/2019/01/Fill-1.png)
relevante of PARADIGM strategic objectives